Patents by Inventor Adam Mor

Adam Mor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS, COMPOSITIONS, KITS AND USES THEREOF TARGETING AND/OR TREATING VRK2 TO ENHANCE EFFECTIVENESS OF IMMUNE CHECKPOINT INHIBITOR(S)
    Publication number: 20220370408
    Abstract: Exemplary methods, compositions, kits and uses thereof for treating neoplasia are provided. For example, a method can be provided for treating neoplasia in a subject, including administering to the subject a VRK2 (vaccinia-related kinase 2) inhibitor, alone or in combination with an inhibitor of Programmed cell death receptor-1 (PD-1). The exemplary methods, compositions and kits may improve cancer immunotherapy.
    Type: Application
    Filed: April 21, 2022
    Publication date: November 24, 2022
    Inventor: ADAM MOR
  • PD-1 related cancer therapy
    Patent number: 11110171
    Abstract: Provided are compositions and methods for identifying individuals with cancer who will benefit from PD-1 inhibitor therapy. The method comprises determining levels of signaling lymphocyte activation molecule-associated protein (SAP) in an individual and based on the SAP levels, determining if the individual is suitable for PD-1 inhibitor therapy. Also provided is a method of treatment of X-linked lymphoproliferative disease comprising administering to an individual PD-1 inhibitory therapy, with or without SHP2 inhibitors.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: September 7, 2021
    Assignee: New York University
    Inventors: Adam Mor, Ben Neel
  • PD-1 RELATED CANCER THERAPY
    Publication number: 20200330595
    Abstract: Provided are compositions and methods for identifying individuals with cancer who will benefit from PD-1 inhibitor therapy. The method comprises determining levels of signaling lymphocyte activation molecule-associated protein (SAP) in an individual and based on the SAP levels, determining if the individual is suitable for PD-1 inhibitor therapy. Also provided is a method of treatment of X-linked lymphoproliferative disease comprising administering to an individual PD-1 inhibitory therapy, with or without SHP2 inhibitors.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 22, 2020
    Inventors: Adam MOR, Ben NEEL
  • USE OF FTS AND ANALOGS TO TREAT NON-AUTOIMMUNE-ALLERGIC AND NON-ALLERGIC INFLAMMATORY CONDITIONS
    Publication number: 20130123365
    Abstract: Disclosed are methods of treating a mammalian subject afflicted with a non-autoimmune inflammatory condition, comprising administering to the subject a pharmaceutical composition comprising an effective amount of S-farnesylthiosalicylic acid (FTS) or a structural analog thereof, and compositions useful in the practice of the methods.
    Type: Application
    Filed: July 7, 2011
    Publication date: May 16, 2013
    Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Yoseph A. Mekori, Adam Mor, Yoel Kloog
  • TREATMENT OF DELAYED CUTANEOUS HYPERSENSITIVITY CONDITIONS WITH S-FARNESYLTHIOSALICYLIC ACID AND ANALOGS THEREOF
    Publication number: 20130116326
    Abstract: Disclosed are methods of treating a mammalian subject afflicted with a delayed cutaneous hypersensitivity condition, comprising administering to the subject a pharmaceutical composition comprising an effective amount of S-farnesylthiosalicylic acid (FTS) or a structural analog thereof, and compositions for use in the methods.
    Type: Application
    Filed: July 7, 2011
    Publication date: May 9, 2013
    Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Yoseph A. Mekori, Adam Mor, Yoel Kloog